A new study details how a nasal spray formulated by investigators from Brigham and Women's Hospital may work to protect ...

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic diseaseKT-621 ...

BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for a ...

HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found ...

Huadong Medicine Co. Ltd. recently revealed data from in vitro and preclinical studies performed to evaluate the efficacy and pharmacokinetic, safety and tolerability profiles of a dual glucagon-like ...

Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and ...

Rakuten Medical Inc. has presented preclinical results with RM-0256, a PD-L1-targeted photoimmunotherapy, showing its ability ...

Halia plans to advance HT-6184 into a Phase 2 clinical trial for obesity later this year. This trial will evaluate the safety, tolerability, and efficacy of HT-6184 in combination with semaglutide for ...

Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore ...